AstraZeneca PLC AZN.ST
Nasdaq Stockholm · Healthcare · Drug Manufacturers - General
1,838.50 SEK
−1.2%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for AstraZeneca
| USD million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 44,351 | 45,811 | 54,073 | 58,739 |
| EBITDA | 9,085 | 13,875 | 15,438 | 19,506 |
| Net income | 3,288 | 5,955 | 7,035 | 10,225 |
| Balance sheet | ||||
| Equity | 37,037 | 39,143 | 40,786 | 48,667 |
| Total debt | 29,143 | 28,407 | 30,114 | 29,149 |
| Cash | 6,166 | 5,840 | 5,488 | 5,711 |
| Net debt | 22,977 | 22,567 | 24,626 | 23,438 |
| Ratios and per share | ||||
| EBITDA margin | 20.5% | 30.3% | 28.6% | 33.2% |
| Profit margin | 7.4% | 13.0% | 13.0% | 17.4% |
| Return on equity | 8.9% | 15.2% | 17.2% | 21.0% |
| Earnings/share (USD) | 2.12 | 3.84 | 4.54 | 6.59 |
| Book value/share (USD) | 23.90 | 25.25 | 26.31 | 31.38 |
| Shares outstanding (M) | 1,550 | 1,550 | 1,550 | 1,551 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 28.2 |
| P/B | 5.9 |
| EV / EBITDA | 16.0 |
| Net debt / EBITDA | 1.2 |
| Return on equity | 21.0% |
| Profit margin | 17.4% |
| Beta 1Y | 0.29 |
| Revenue growth 1Y | +8.6% |
| Revenue CAGR 3Y | +9.8% |
| Earnings/share CAGR 3Y | +45.9% |
| ROE avg. 3Y | 17.8% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (SEK)
| 2026 | 31.35 |
| 2025 | 32.10 |
| 2024 | 30.64 |
| 2023 | 30.77 |
| 2022 | 29.08 |
Not investment advice. Figures may contain errors from the data source.